Cargando…

Combination of Dll4/Notch and Ephrin-B2/EphB4 targeted therapy is highly effective in disrupting tumor angiogenesis

BACKGROUND: Dll4/Notch and Ephrin-B2/EphB4 pathways play critical roles in tumor vessel development and maturation. This study evaluates the efficacy of the inhibition of both signaling pathways, alone and in combination, in reducing the growth of an autochthonous mouse tumor and assesses potential...

Descripción completa

Detalles Bibliográficos
Autores principales: Djokovic, Dusan, Trindade, Alexandre, Gigante, Joana, Badenes, Marina, Silva, Lilliana, Liu, Ren, Li, Xiuqing, Gong, Ming, Krasnoperov, Valery, Gill, Parkash S, Duarte, Antonio
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3001720/
https://www.ncbi.nlm.nih.gov/pubmed/21092311
http://dx.doi.org/10.1186/1471-2407-10-641
_version_ 1782193653218803712
author Djokovic, Dusan
Trindade, Alexandre
Gigante, Joana
Badenes, Marina
Silva, Lilliana
Liu, Ren
Li, Xiuqing
Gong, Ming
Krasnoperov, Valery
Gill, Parkash S
Duarte, Antonio
author_facet Djokovic, Dusan
Trindade, Alexandre
Gigante, Joana
Badenes, Marina
Silva, Lilliana
Liu, Ren
Li, Xiuqing
Gong, Ming
Krasnoperov, Valery
Gill, Parkash S
Duarte, Antonio
author_sort Djokovic, Dusan
collection PubMed
description BACKGROUND: Dll4/Notch and Ephrin-B2/EphB4 pathways play critical roles in tumor vessel development and maturation. This study evaluates the efficacy of the inhibition of both signaling pathways, alone and in combination, in reducing the growth of an autochthonous mouse tumor and assesses potential adverse effects. METHODS: We used the transgenic RIP1-Tag2 tumor model to study the effects of 1) inhibition of Dll4/Notch by either Dll4 allelic deletion or use of a soluble extracellular Dll4 (sDll4), 2) inhibition of Ephrin-B2/EphB4 signaling by a soluble extracellular EphB4 fused to albumin (sEphB4-Alb), and 3) inhibition of both pathways by sEphB4-Alb combined with either Dll4 allelic deletion or sDll4. To investigate adverse effects, we used inducible endothelial-specific Dll4 knock-out mice, treated with sEphB4-Alb, and carried out histopathological analysis. RESULTS: Dll4 allele deletion or soluble Dll4 treatment resulted in increased tumor vessel density, reduced mural cell recruitment and vessel perfusion which resulted in reduced tumor size. The soluble EphB4 instead reduced vessel density and vessel perfusion, leading to reduction of tumor size. Greater efficacy was observed when sEphB4-Alb was combined with either Dll4 allele deletion or sDll4 in regards to tumor size, vessel perfusion and mural cell recruitment. Induced endothelial specific Dll4 loss-of-function caused hepatic vascular alterations, which were prevented by concomitant sEphB4-Alb treatment. CONCLUSION: Combination targeting of Dll4/Notch and Ephrin-B2/EphB4 has potential for clinical investigation, providing cumulative efficacy and increased safety over Dll4/Notch inhibition alone.
format Text
id pubmed-3001720
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-30017202010-12-15 Combination of Dll4/Notch and Ephrin-B2/EphB4 targeted therapy is highly effective in disrupting tumor angiogenesis Djokovic, Dusan Trindade, Alexandre Gigante, Joana Badenes, Marina Silva, Lilliana Liu, Ren Li, Xiuqing Gong, Ming Krasnoperov, Valery Gill, Parkash S Duarte, Antonio BMC Cancer Research Article BACKGROUND: Dll4/Notch and Ephrin-B2/EphB4 pathways play critical roles in tumor vessel development and maturation. This study evaluates the efficacy of the inhibition of both signaling pathways, alone and in combination, in reducing the growth of an autochthonous mouse tumor and assesses potential adverse effects. METHODS: We used the transgenic RIP1-Tag2 tumor model to study the effects of 1) inhibition of Dll4/Notch by either Dll4 allelic deletion or use of a soluble extracellular Dll4 (sDll4), 2) inhibition of Ephrin-B2/EphB4 signaling by a soluble extracellular EphB4 fused to albumin (sEphB4-Alb), and 3) inhibition of both pathways by sEphB4-Alb combined with either Dll4 allelic deletion or sDll4. To investigate adverse effects, we used inducible endothelial-specific Dll4 knock-out mice, treated with sEphB4-Alb, and carried out histopathological analysis. RESULTS: Dll4 allele deletion or soluble Dll4 treatment resulted in increased tumor vessel density, reduced mural cell recruitment and vessel perfusion which resulted in reduced tumor size. The soluble EphB4 instead reduced vessel density and vessel perfusion, leading to reduction of tumor size. Greater efficacy was observed when sEphB4-Alb was combined with either Dll4 allele deletion or sDll4 in regards to tumor size, vessel perfusion and mural cell recruitment. Induced endothelial specific Dll4 loss-of-function caused hepatic vascular alterations, which were prevented by concomitant sEphB4-Alb treatment. CONCLUSION: Combination targeting of Dll4/Notch and Ephrin-B2/EphB4 has potential for clinical investigation, providing cumulative efficacy and increased safety over Dll4/Notch inhibition alone. BioMed Central 2010-11-23 /pmc/articles/PMC3001720/ /pubmed/21092311 http://dx.doi.org/10.1186/1471-2407-10-641 Text en Copyright ©2010 Djokovic et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<url>http://creativecommons.org/licenses/by/2.0</url>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Djokovic, Dusan
Trindade, Alexandre
Gigante, Joana
Badenes, Marina
Silva, Lilliana
Liu, Ren
Li, Xiuqing
Gong, Ming
Krasnoperov, Valery
Gill, Parkash S
Duarte, Antonio
Combination of Dll4/Notch and Ephrin-B2/EphB4 targeted therapy is highly effective in disrupting tumor angiogenesis
title Combination of Dll4/Notch and Ephrin-B2/EphB4 targeted therapy is highly effective in disrupting tumor angiogenesis
title_full Combination of Dll4/Notch and Ephrin-B2/EphB4 targeted therapy is highly effective in disrupting tumor angiogenesis
title_fullStr Combination of Dll4/Notch and Ephrin-B2/EphB4 targeted therapy is highly effective in disrupting tumor angiogenesis
title_full_unstemmed Combination of Dll4/Notch and Ephrin-B2/EphB4 targeted therapy is highly effective in disrupting tumor angiogenesis
title_short Combination of Dll4/Notch and Ephrin-B2/EphB4 targeted therapy is highly effective in disrupting tumor angiogenesis
title_sort combination of dll4/notch and ephrin-b2/ephb4 targeted therapy is highly effective in disrupting tumor angiogenesis
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3001720/
https://www.ncbi.nlm.nih.gov/pubmed/21092311
http://dx.doi.org/10.1186/1471-2407-10-641
work_keys_str_mv AT djokovicdusan combinationofdll4notchandephrinb2ephb4targetedtherapyishighlyeffectiveindisruptingtumorangiogenesis
AT trindadealexandre combinationofdll4notchandephrinb2ephb4targetedtherapyishighlyeffectiveindisruptingtumorangiogenesis
AT gigantejoana combinationofdll4notchandephrinb2ephb4targetedtherapyishighlyeffectiveindisruptingtumorangiogenesis
AT badenesmarina combinationofdll4notchandephrinb2ephb4targetedtherapyishighlyeffectiveindisruptingtumorangiogenesis
AT silvalilliana combinationofdll4notchandephrinb2ephb4targetedtherapyishighlyeffectiveindisruptingtumorangiogenesis
AT liuren combinationofdll4notchandephrinb2ephb4targetedtherapyishighlyeffectiveindisruptingtumorangiogenesis
AT lixiuqing combinationofdll4notchandephrinb2ephb4targetedtherapyishighlyeffectiveindisruptingtumorangiogenesis
AT gongming combinationofdll4notchandephrinb2ephb4targetedtherapyishighlyeffectiveindisruptingtumorangiogenesis
AT krasnoperovvalery combinationofdll4notchandephrinb2ephb4targetedtherapyishighlyeffectiveindisruptingtumorangiogenesis
AT gillparkashs combinationofdll4notchandephrinb2ephb4targetedtherapyishighlyeffectiveindisruptingtumorangiogenesis
AT duarteantonio combinationofdll4notchandephrinb2ephb4targetedtherapyishighlyeffectiveindisruptingtumorangiogenesis